JMI LABS IS NOW PART OF LEARN MORE

Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor (PDI)

Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor (PDI), Lead author: Fritsche TR, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Antimicrobial Activity of LBM 415 (NVP PDF-713) Tested against Neisseria meningitidis (NM) and N. gonorrhoeae (NG)

Antimicrobial Activity of LBM 415 (NVP PDF-713) Tested against Neisseria meningitidis (NM) and N. gonorrhoeae (NG), Lead author: Rhomberg PR, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Antimicrobial Activity and Spectrum of PPI-0903 (TAK-599), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

Antimicrobial Activity and Spectrum of PPI-0903 (TAK-599), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains, Lead author: Sader HS, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Evaluation of PPI-0903 (TAK-599), a Novel Cephalosporin: Bactericidal Activity, Effects of Modifying Testing Parameters and Optimization of Disk Diffusion Tests

Evaluation of PPI-0903 (TAK-599), a Novel Cephalosporin: Bactericidal Activity, Effects of Modifying Testing Parameters and Optimization of Disk Diffusion Tests, Lead author: Sader HS, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Evaluating Antimicrobial (ABX) Use & Bacterial Resistance (R): Comparison of the Statistical Power Achieved for Different Regression Methods

Evaluating Antimicrobial (ABX) Use & Bacterial Resistance (R): Comparison of the Statistical Power Achieved for Different Regression Methods, Lead author: Bhavnani SM, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Evaluation of Patients with ESBL- and Non-ESBL Producing Enterobacteriaceae (ETB): Outcomes Report from the SENTRY Antimicrobial Surveillance Program

Evaluation of Patients with ESBL- and Non-ESBL Producing Enterobacteriaceae (ETB): Outcomes Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Bhavnani SM, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

An Outbreak of Catalase-Negative Methicillin-Resistant Staphylococcus aureus

An Outbreak of Catalase-Negative Methicillin-Resistant Staphylococcus aureus, Lead author: Gales AC, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Validation of Etest for Antifungal Susceptibility Testing of 3 Agents using the FDA 510(k) Criteria for Antimicrobial Susceptibility Test (AST) Devices

Validation of Etest for Antifungal Susceptibility Testing of 3 Agents using the FDA 510(k) Criteria for Antimicrobial Susceptibility Test (AST) Devices, Lead author: Bolmstrom A, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Antifungal Susceptibility Results from a Worldwide Anidulafungin Surveillance Program (2002-2003)

Antifungal Susceptibility Results from a Worldwide Anidulafungin Surveillance Program (2002-2003), Lead author: Messer S, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003)

International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003), Lead author: Messer S, presented at 44th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), October 30 – November 2, 2004, Washington, DC

Doripenem (DOR) International Surveillance: Antimicrobial Activity Against 16,008 Contemporary Pathogens (2003)

Doripenem (DOR) International Surveillance: Antimicrobial Activity Against 16,008 Contemporary Pathogens (2003), Lead author: Fritsche TR, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Evaluation of the Reproducibility of MIC Results of Selected Newer Fluoroquinolones in Commercial Dry-Form Panels for Clinical Use

Evaluation of the Reproducibility of MIC Results of Selected Newer Fluoroquinolones in Commercial Dry-Form Panels for Clinical Use, Lead author: Jones RN, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Monitoring For Antimicrobial Resistance in North American Haematology-Oncology Centers: Results from the CANCER Resistance Surveillance Program (USA; 2000-2002)

Monitoring For Antimicrobial Resistance in North American Haematology-Oncology Centers: Results from the CANCER Resistance Surveillance Program (USA; 2000-2002), Lead author: Fritsche TR, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Antimicrobial Activity of Daptomycin Tested Against Clinical Strains of Indicated Species Isolated in North American Medical Centers (2003)

Antimicrobial Activity of Daptomycin Tested Against Clinical Strains of Indicated Species Isolated in North American Medical Centers (2003), Lead author: Sader HS, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Inter-Method Comparison of Broth Microdilution and Agar Dilution Testing for Campylobacter spp.: Standardization of Broth Methods

Inter-Method Comparison of Broth Microdilution and Agar Dilution Testing for Campylobacter spp.: Standardization of Broth Methods, Lead author: Fritsche TR, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Activity of Tigecycline (TIG) Tested Against Non-Fermentative Gram-negative (NFB) Bacilli other than P. aeruginosa

Activity of Tigecycline (TIG) Tested Against Non-Fermentative Gram-negative (NFB) Bacilli other than P. aeruginosa, Lead author: Fritsche TR, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Antimicrobial Susceptibility of P. aeruginosa and Acinetobacter spp. from Bloodstream Infections (BSI): Comparison of SENTRY Program Results from North America, Latin America and Europe

Antimicrobial Susceptibility of P. aeruginosa and Acinetobacter spp. from Bloodstream Infections (BSI): Comparison of SENTRY Program Results from North America, Latin America and Europe, Lead author: Sader HS, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Multi-Drug Resistant Pseudomonas aeruginosa, Co-Resistances in MYSTIC and SENTRY Programs

Multi-Drug Resistant Pseudomonas aeruginosa, Co-Resistances in MYSTIC and SENTRY Programs, Lead author: Jones RN, presented at 42nd annual Infectious Diseases Society of America (IDSA), September 30 – October 3, 2004, Boston, MA

Influence of Patient Age on the Occurrence and Antimicrobial Resistance Trends of Isolates from Haemotology/Oncology Patients: Second Report from the CANCER Program (2001-2002)

Influence of Patient Age on the Occurrence and Antimicrobial Resistance Trends of Isolates from Haemotology/Oncology Patients: Second Report from the CANCER Program (2001-2002), Lead author: Sader HS, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Susceptibility Testing Characteristics and Quality Control (QC) Guidelines for Omiganan Pentahydrochloride, A Topical Cationic Peptide

Susceptibility Testing Characteristics and Quality Control (QC) Guidelines for Omiganan Pentahydrochloride, A Topical Cationic Peptide, Lead author: Rennie R, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Antimicrobial Potency and Spectrum of Meropenem Versus Eleven Broad-Spectrum Agents: Report from the United States (US) MYSTIC Program (2003)

Antimicrobial Potency and Spectrum of Meropenem Versus Eleven Broad-Spectrum Agents: Report from the United States (US) MYSTIC Program (2003), Lead author: Rhomberg PR, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Dalbavancin MIC Testing: Validation and Test Reproducibility of Commercial Reagents

Dalbavancin MIC Testing: Validation and Test Reproducibility of Commercial Reagents, Lead author: Fritsche TR, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Occurrence, Persistence and Influence of Resistant Gram-Negative Clones: Report from the MYSTIC Programme (2003)

Occurrence, Persistence and Influence of Resistant Gram-Negative Clones: Report from the MYSTIC Programme (2003), Lead author: Jones RN, presented at 104th annual American Society for Microbiology General Meeting (ASM), May 23 – 27, 2004, New Orleans, LA

Analysis of the flexible loop of the SPM-1 metallo-beta-lactamase in substrate binding and hydrolysis

Analysis of the flexible loop of the SPM-1 metallo-beta-lactamase in substrate binding and hydrolysis, Lead author: Murphy TA, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Incidence of fluoroquinolone-resistant beta-haemolytic Streptococci in North America (NA) and Europe (EU): Report from the SENTRY Antimicrobial Surveillance Program, 1997-2002

Incidence of fluoroquinolone-resistant beta-haemolytic Streptococci in North America (NA) and Europe (EU): Report from the SENTRY Antimicrobial Surveillance Program, 1997-2002, Lead author: Biedenbach DJ, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Role of clonal occurrences of multi-drug-resistance (MDR) in the MYSTIC Programme (USA; 1999-2003)

Role of clonal occurrences of multi-drug-resistance (MDR) in the MYSTIC Programme (USA; 1999-2003), Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Tn21-like elements disseminating carbapenemase genes in Italy: report from the SENTRY antimicrobial surveillance programme

Tn21-like elements disseminating carbapenemase genes in Italy: report from the SENTRY antimicrobial surveillance programme, Lead author: Toleman MA, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Contribution of outer membrane protein alterations and beta-lactamases in carbapenem-resistant Acinetobacter spp.

Contribution of outer membrane protein alterations and beta-lactamases in carbapenem-resistant Acinetobacter spp., Lead author: Castanheira M, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Characterisation of two novels 6′-N-aminoglycoside acetyltransferase genes, aac(6′)-30 and aac(6′)-31, found in blaIMP-16 and blaIMP-1 Pseudomonas aeruginosa strains carrying integron

Characterisation of two novels 6′-N-aminoglycoside acetyltransferase genes, aac(6′)-30 and aac(6′)-31, found in blaIMP-16 and blaIMP-1 Pseudomonas aeruginosa strains carrying integron, Lead author: Mendes RE, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Characterisation of In77, a class 1 plasmid-located integron carrying the novel metallo-beta-latamase gene blaGIM-1

Characterisation of In77, a class 1 plasmid-located integron carrying the novel metallo-beta-latamase gene blaGIM-1, Lead author: Castanheira M, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Tn501-like transposons carrying novel blaVIM-4 metallo-&#223-lactamase (MBL) gene cassettes in Poland and GIM-1 in Germany: report from the SENTRY antimicrobial surveillance programme

Tn501-like transposons carrying novel blaVIM-4 metallo-&#223-lactamase (MBL) gene cassettes in Poland and GIM-1 in Germany: report from the SENTRY antimicrobial surveillance programme, Lead author: Toleman MA, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Biochemical characterisation of VIM-7, a new VIM variant produced by a Pseudomomas aeruginosa clinical isolate from Texas

Biochemical characterisation of VIM-7, a new VIM variant produced by a Pseudomomas aeruginosa clinical isolate from Texas, Lead author: Castanheira M, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Daptomycin in vitro activity tested against 2,221 Gram-positive strains collected from European hospitals, 2002

Daptomycin in vitro activity tested against 2,221 Gram-positive strains collected from European hospitals, 2002, Lead author: Sader HS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Pharmacodynamics of levofloxacin (usual and high dose) and moxifloxacin versus Streptococcus pneumoniae from the SENTRY antimicrobial surveillance program (2002-2003) in elderly patients using Monte Carlo Analysis and population pharmacokinetics

Pharmacodynamics of levofloxacin (usual and high dose) and moxifloxacin versus Streptococcus pneumoniae from the SENTRY antimicrobial surveillance program (2002-2003) in elderly patients using Monte Carlo Analysis and population pharmacokinetics, Lead author: Owens Jr. RC, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

The emergence of VIM-2 in Latin American hospitals: report from the SENTRY Antimicrobial Surveillance Program

The emergence of VIM-2 in Latin American hospitals: report from the SENTRY Antimicrobial Surveillance Program, Lead author: Mendes RE, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Endemic and epidemic occurrences of metallo-beta-lactamases in Japanese medical centres (1998-2002): report from the SENTRY Antimicrobial Surveillance Program

Endemic and epidemic occurrences of metallo-beta-lactamases in Japanese medical centres (1998-2002): report from the SENTRY Antimicrobial Surveillance Program, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial activity of the novel cephalosporin LB11058 tested against pathogens commonly associated with bacterial meningitis

Antimicrobial activity of the novel cephalosporin LB11058 tested against pathogens commonly associated with bacterial meningitis, Lead author: Sader HS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Substrate inhibition of the Pseudomonas aeruginosa metallo-beta-lactamase, SPM-1, in acidic and alkaline conditions

Substrate inhibition of the Pseudomonas aeruginosa metallo-beta-lactamase, SPM-1, in acidic and alkaline conditions, Lead author: Murphy TA, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Biochemical characterisation of IMP-16, a novel IMP variant harboured in a class I integron of a Pseudomonas aeruginosa clinical isolate from Brazil

Biochemical characterisation of IMP-16, a novel IMP variant harboured in a class I integron of a Pseudomonas aeruginosa clinical isolate from Brazil, Lead author: Mendes RE, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Frequency and antimicrobial susceptibility of bacterial pathogens isolated from bloodstream infections in haematology-oncology patients: results from the Latin America SENTRY Antimicrobial Surveillance Program (1997-2002)

Frequency and antimicrobial susceptibility of bacterial pathogens isolated from bloodstream infections in haematology-oncology patients: results from the Latin America SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Andrade SS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Frequency of occurrence and antimicrobial susceptibility profile of pathogens causing bloodstream infections in paediatric patients from Latin America: report of SENTRY Antimicrobial Surveillance Program (1997-2002)

Frequency of occurrence and antimicrobial susceptibility profile of pathogens causing bloodstream infections in paediatric patients from Latin America: report of SENTRY Antimicrobial Surveillance Program (1997-2002), Lead author: Gales AC, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial spectrum and activity of NVP PDF-713 (PDF7), a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates

Antimicrobial spectrum and activity of NVP PDF-713 (PDF7), a novel peptide deformylase inhibitor, tested against 1,837 recent Gram-positive clinical isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Potential utility of a peptide deformylase inhibitor, NVP PDF-713 (PDF7) against oxazolidinone-resistant or streptogramin-resistant Gram-positive isolates

Potential utility of a peptide deformylase inhibitor, NVP PDF-713 (PDF7) against oxazolidinone-resistant or streptogramin-resistant Gram-positive isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Determination of quality control guidelines for MIC dilution and disk diffusion methods when testing NVP-PDF713, a novel peptide deformylase inhibitor

Determination of quality control guidelines for MIC dilution and disk diffusion methods when testing NVP-PDF713, a novel peptide deformylase inhibitor, Lead author: Fritsche TR, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Determination of dry-form commercial reagent reproducibility and MIC validations for NVP-PDF713, a novel peptide deformylase inhibitor

Determination of dry-form commercial reagent reproducibility and MIC validations for NVP-PDF713, a novel peptide deformylase inhibitor, Lead author: Moet G, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Once-weekly dalbavancin in catheter-related bloodstream infections: microbiological findings

Once-weekly dalbavancin in catheter-related bloodstream infections: microbiological findings, Lead author: Goldstein BP, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Evaluations of Dalbavancin (DAL) activity and spectrum tested against European isolates

Evaluations of Dalbavancin (DAL) activity and spectrum tested against European isolates, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

In vitro activity of the glycylcycline tigecycline tested against a worldwide collection of 10,127 contemporary Staphylococci, Streptococci and Enterococci

In vitro activity of the glycylcycline tigecycline tested against a worldwide collection of 10,127 contemporary Staphylococci, Streptococci and Enterococci, Lead author: Fritsche TR, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Antimicrobial activity of tigecycline (GAR-936) tested against enterobacteriaceae, and selected non-fermentative Gram-negative bacilli, a worldwide sample

Antimicrobial activity of tigecycline (GAR-936) tested against enterobacteriaceae, and selected non-fermentative Gram-negative bacilli, a worldwide sample, Lead author: Jones RN, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic

Activity of tigecycline tested against clinical isolates of Haemophilus influenzae, Moraxella catarrhalis and Neisseria menigitidis, a worldwide perspective

Activity of tigecycline tested against clinical isolates of Haemophilus influenzae, Moraxella catarrhalis and Neisseria menigitidis, a worldwide perspective, Lead author: Sader HS, presented at 14th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 1 – 4, 2004, Prague, Czech Republic